Taken together, these results demonstrate a novel role for BCV in lymphoma therapy and suggest potential for combination with checkpoint immunotherapy.

P2, N=160, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028

Furthermore, depletion of THBS2+ fibroblasts enhanced polyp formation but suppressed tumor formation in a thymidine kinase 1/ganciclovir/azoxymethane/dextran sulfate sodium mouse model. The comprehensive multi-omics atlas and complementary data presented here will advance our understanding of the mechanisms underlying CRC malignant transformation and may provide a potential therapeutic target.

P3, N=180, Not yet recruiting, SymBio Pharmaceuticals

The herpes simplex virus thymidine kinase/ganciclovir (HSV-TK/GCV) suicide gene therapy system has shown promise in cancer treatment, but its clinical applicability is limited by off-target cytotoxicity...In two orthotopic breast cancer models, BRAS significantly suppressed tumor growth without affecting body weight or general health, underscoring its therapeutic potential. This approach intelligently combines molecular signals from both cancerous and healthy cells to precisely regulate therapeutic gene expression, making it a promising platform for the next-generation cancer therapy.

P2, N=26, Recruiting, OHSU Knight Cancer Institute | Not yet recruiting --> Recruiting

P=N/A, N=30, Not yet recruiting, Beijing Chaoyang Hospital, Capital Medical University; Beijing Chaoyang Hospital, Capital Medical University

P=N/A, N=184, Not yet recruiting, Beijing Hospital; Beijing Hospital

We predicted potential therapeutic small molecular drugs by targeting subtype-specific oncogenic pathways and validated drug sensitivity (C1-GBM: Methotrexate and Cisplatin; C2-GBM: Cytarabine) by assessing IC50 values against GBM cell lines (divided into C1/C2 subtypes based on the nine hub genes) from the Genomics of Drug Sensitivity in Cancer database. This study introduces a pathway-based prognostic molecular classification of GBM with "hot" (C1-GBM) and "inherent driving" (C2-GBM) tumor subtypes, providing a prediction model based on hub biomarkers and potential therapeutic targets for treatments.

P=N/A, N=153, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2025 --> Dec 2026

By targeting nucleic acids, FLT3 or CD33, several FDA-approved NPs and NPDs (i.e., cytarabine, anthracyclines, midostaurin, melphalan and calicheamicin linked to anti-CD33) are the major agents of upfront treatment of AML. This review summarizes the current state of the art, and provides a summary of selected NPs/NPDs which are either entering or have been investigated in preclinical and clinical trials, alone or in combination with current chemotherapy. With multifaceted actions, these biomolecules may target all hallmarks of AML, including multidrug resistance and deregulated metabolism.

P3, N=167, Terminated, Delta-Fly Pharma, Inc. | N=450 --> 167 | Trial completion date: Jun 2026 --> Jan 2026 | Recruiting --> Terminated; The data met the protocol-specified criteria for futility of the investigational treatment.